Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Objective: To examine the clinical characteristics and anemia-related factors in patients with newly diagnosed multiple myeloma (NDMM), as well as the effect and mechanism of erythroblastic islands (EBIs) and EBI macrophages in NDMM patients with anemia.

Methods: We collected and analyzed clinical data to find anemia-related factors. Using flow cytometry, the numbers and ratios of erythroblasts and EBI macrophages were determined. RNA sequencing (RNA-seq) was used to determine the differences of EBI macrophages in NDMM patients with or without anemia.

Results: Based on the clinical characteristics of NDMM patients with anemia, MCV, abnormal levels of albumin, osteolytic lesions, and Durie-Salmon (DS) stage are risk factors for anemia. Patients with anemia have fewer erythroblasts, erythroblastic islands (EBIs), and EBI macrophages in their bone marrow than patients without anemia. RNA-seq analysis of EBI macrophages from the bone marrow of patients with and without anemia revealed that macrophages from patients with anemia are impaired and tend to promote the production of interleukin-6, which has been demonstrated to be an essential survival factor of myeloma cells and protects them from apoptosis.

Conclusion: In NDMM patients with anemia, EBI macrophages are impaired, which causes anemia in those patients. Our finding highlights the significance of EBI macrophages in anemia in NDMM patients and provides a new strategy for recovery from anemia in these patients.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10284299PMC
http://dx.doi.org/10.2147/JIR.S413044DOI Listing

Publication Analysis

Top Keywords

ebi macrophages
28
patients anemia
24
ndmm patients
20
anemia patients
16
patients
13
anemia
11
macrophages
9
mechanism erythroblastic
8
macrophages anemia
8
patients newly
8

Similar Publications

Inhibiting KRAS with CD47 and immune checkpoint overcomes intrinsic resistance to combined KRAS and immune checkpoint inhibitor therapy.

Cell Rep Med

August 2025

Division of Molecular Therapeutics, Aichi Cancer Center Research Institute, Nagoya 464-8681, Japan; Division of Advanced Cancer Therapeutics, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan. Electronic address:

Although Kirsten rat sarcoma virus (KRAS) G12C inhibitors alter the treatment strategy for patients with KRAS G12C-mutant lung cancer, their efficacy remains insufficient to eliminate tumors. Here, we identify that inhibition of mutant KRAS promotes escape from macrophage phagocytosis by upregulating the expression of cluster of differentiation 47 (CD47) and CD24. These proteins are induced by the binding of FOXA1 to the super-enhancer of CD47 and grainyhead-like transcription factor 2 (GRHL2) to the promoter of CD24, respectively.

View Article and Find Full Text PDF

Background: Stroke is the second leading cause of death and the third leading cause of disability worldwide. The role of fibroblast growth factor 5 (FGF5) in the occurrence and development of stroke remains unclear. We used bidirectional Mendelian randomization (MR) analysis to evaluate the mediating role of metabolites and causal association between inflammatory factors and stroke.

View Article and Find Full Text PDF

Atherosclerosis is characterized by chronic inflammation and plaque formation in arterial walls, accompanying by significant involvement of immune cells and mediators. Studies have demonstrated that factors, such as colony-stimulating factor-1, play critical roles in the development and exacerbation of these plaques, emphasizing the complexity of immune interactions in atherosclerosis. This study utilized GSE198600, GSE120521, GSE253903, and GSE224273 datasets to investigate the gene expression profiles and molecular mechanisms underlying atherosclerotic plaques.

View Article and Find Full Text PDF

Background: The myocyte enhancer factor-2 (MEF2) family genes were involved in the carcinogenesis and prognosis of multiple human tumors. The impact of MEF2s on the occurrences, progression, and clinical outcome of pancreatic cancer (PAAD) remains unknown.

Methods: This study used the CCLE, HPA, EMBL-EBI, and GEPIA2 databases to study MEF2s expression in PAAD patients.

View Article and Find Full Text PDF

Erythroblastic island: the niche for erythroid terminal differentiation and beyond.

Blood Sci

June 2025

State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, 288 Nanjing Road, Tianjin 300020, China.

The erythroblastic island (EBI) is a multicellular structure defined by the presence of 1 or 2 central macrophages surrounded by at least 3 erythroblasts. EBIs were initially proposed as a specialized microenvironment exclusively for erythroid terminal differentiation. Recent advancements in techniques such as lineage tracing mouse models, imaging flow cytometry, and single-cell RNA sequencing, accumulating evidence has provided novel insights that challenge this conventional view.

View Article and Find Full Text PDF